SPARC2024-01-012024-03-31 SPARC2024-01-012024-03-31 SPARC2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member SPARC2024-01-012024-03-31in-bse-fin:OneOperatingExpenses02Member SPARC2024-01-012024-03-31in-bse-fin:OneOperatingExpenses03Member SPARC2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member SPARC2024-01-012024-03-31in-bse-fin:FourOperatingExpenses02Member SPARC2024-01-012024-03-31in-bse-fin:FourOperatingExpenses03Member SPARC2024-03-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532872 SPARC NA Sun Pharma Advanced Research Company Limited Equity 2023-04-01 2024-03-31 2024-05-24 2024-05-17 INR Lakhs Yearly 16:30:00 20:00:00 2024-05-24 2024-05-24 true Cash Flow Indirect Declaration of unmodified opinion Single segment Pharmaceutical Research and Development 2024-01-01 2024-03-31 Audited Standalone 165600000.00 44000000.00 209600000.00 74600000.00 0.00 0.00 267200000.00 8800000.00 26900000.00 899000000.00 1276500000.00 -1066900000.00 0.00 -1066900000.00 0.00 0.00 0.00 0.00 -1066900000.00 0.00 0.00 0.00 0.00 -1066900000.00 -8300000.00 -1075200000.00 0.00 0.00 324500000.00 1 -3.29 -3.29 0.00 0.00 -3.29 -3.29 1. The above audited standalone financial results of Sun Pharma Advanced Research Company Limited (the 'Company') have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have been taken on record by the Board of Directors at its meeting held on May 24, 2024 after being reviewed by the Audit Committee. 2. During the quarter ended March 31, 2023, the Company had paused the development of SCO-120 program due to changing clinical landscape. Pursuant to this, the Company had made provision for committed costs for this program estimated amounting to 2,700 lakhs. During the quarter ended September 30, 2023, basis the final settlement, the Company reversed an excess provision of 324 lakhs. 3. The Company has incurred cash losses in past years and in the current year. However, the Company has unutilized credit limits from banks (which are guaranteed by its Promoter Group Entity) and from its promoter group entity, to support its operations. Further, the Company has also received a financial support letter from its Promoter Group Entity to ensure its status as Going Concern and the continuance of its operations, as and when required. 4. On April 10, 2024, the Company has intimated the results of interim analysis of PROSEEK study relating to Parkinson disease project (K0706). The study failed to demonstrate superiority of Vodobatinib in the pre-specified primary endpoint as compared to placebo. The Company plans to complete the full analysis of clinical outcomes and correlative biomarker data in the coming months. The Company believes that all impacts of this study on its financial statements , relevant for the year and quarter ended March 31, 2024 have been considered. 5. The Company has only one reportable business segment namely 'Pharmaceutical Research & Development'. 6. The figures for the quarter ended March 31, 2024 and March 31, 2023 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the relevant financial years which was subject to limited review by the Statutory Auditors of the Company. 7. Previous period figures have been regrouped / reclassified, wherever considered necessary. Single segment 2023-04-01 2024-03-31 Audited Standalone 755500000.00 294700000.00 1050200000.00 281300000.00 0.00 0.00 1185300000.00 16600000.00 121300000.00 3326800000.00 4931300000.00 -3881100000.00 0.00 -3881100000.00 0.00 0.00 0.00 0.00 -3881100000.00 0.00 0.00 0.00 0.00 -3881100000.00 1900000.00 -3879200000.00 0.00 0.00 324500000.00 1 4803200000.00 -11.96 -11.96 0.00 0.00 -11.96 -11.96 Clinical trial expenses / products development expense 224500000.00 Other expenses 116100000.00 Professional charges 558400000.00 Clinical trial expenses / products development expense 1013500000.00 Other expenses 524400000.00 Professional charges 1788900000.00 1024600000.00 12600000.00 0.00 0.00 1900000.00 425300000.00 0.00 4200000.00 0.00 0.00 0.00 254900000.00 254900000.00 0.00 675800000.00 2399300000.00 0.00 18000000.00 155300000.00 50600000.00 1500000000.00 2200000.00 206700000.00 1932800000.00 0.00 531200000.00 2464000000.00 4863300000.00 324500000.00 924000000.00 1248500000.00 1248500000.00 0.00 0.00 80400000.00 80400000.00 60500000.00 0.00 0.00 1035000000.00 1175900000.00 470000000.00 1498200000.00 284600000.00 2252800000.00 150600000.00 35500000.00 0.00 0.00 2438900000.00 3614800000.00 4863300000.00 16600000.00 0.00 152100000.00 0.00 -405500000.00 0.00 0.00 -31800000.00 0.00 15800000.00 0.00 27200000.00 0.00 121300000.00 0.00 -48500000.00 0.00 0.00 0.00 20700000.00 0.00 254700000.00 0.00 0.00 0.00 0.00 0.00 14700000.00 0.00 -372100000.00 -4253200000.00 0.00 0.00 0.00 41100000.00 0.00 -4294300000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4900000.00 265100000.00 2841900000.00 4200000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 223700000.00 0.00 1109900000.00 0.00 3911100000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 644100000.00 174600000.00 0.00 25900000.00 0.00 15600000.00 0.00 0.00 428000000.00 44800000.00 0.00 44800000.00 5800000.00 50600000.00 8300000.00 -1900000.00 0.00 0.00